Join

Compare · NVO vs XENE

NVO vs XENE

Side-by-side comparison of Novo Nordisk A/S (NVO) and Xenon Pharmaceuticals Inc. (XENE): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both NVO and XENE operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • NVO is the larger of the two at $215.46B, about 36.8x XENE ($5.85B).
  • NVO has been more active in the news (9 items in the past 4 weeks vs 7 for XENE).
  • NVO has more recent analyst coverage (25 ratings vs 19 for XENE).
MetricNVOXENE
Company
Novo Nordisk A/S
Xenon Pharmaceuticals Inc.
Price
-
-
Market cap
$215.46B
$5.85B
1M return
-
-
1Y return
-
-
Sector
Health Care
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NYSE
NASDAQ
IPO
2014
News (4w)
9
7
Recent ratings
25
19
NVO

Novo Nordisk A/S

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

XENE

Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel modulator that is Phase III clinical trials for the treatment of KCNQ2 epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel modulator, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop FX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. The company was incorporated in 1996 and is headquartered in Burnaby, Canada.

Latest NVO

Latest XENE